Conference Correspondent

Treatment of elderly and/or unfit chronic lymphocytic leukemia (CLL) patients with chlorambucil plus rituximab was associated with low toxicity, a high overall response rate, and durable progression-free survival, suggesting that in low-risk unfit patients, this combination may be an optimal therapeutic option taking into consideration safety, efficacy, and cost.
Healthcare utilization of elderly chronic lymphocytic leukemia (CLL) patients who remain on bendamustine-rituximab (BR) is significantly lower than patients who remain on fludarabine, cyclophosphamide, and rituximab (FCR), with FCR-treated patients experiencing significantly more days of hospitalization, outpatient visits, and emergency department visits than BR-treated patients.
In an effort to determine whether lower peripheral neuropathy rates could be achieved, this study evaluated the efficacy and safety of subcutaneous bortezomib in combination with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma.
Using a novel electronic health record database that included nearly 800 chronic lymphocytic leukemia patients, recent treatment patterns in the United States showed a decline in the use of fludarabine-, bendamustine-, and rituximab-containing regimens and a significant increase in the use of obinutuzumab and ibrutinib, either as monotherapy or in combination regimens.
Heavily pretreated patients with relapsed or refractory multiple myeloma (RRMM) derived significant benefit from a combination of daratumumab, dexamethasone, and bortezomib. These data continue to support the addition of daratumumab to a standard-of-care regimen in RRMM.

Administration of the asthma medication montelukast more than 30 minutes before infusion of daratumumab can drastically reduce infusion-related reactions in patients with multiple myeloma.

In a subgroup analysis of the POLLUX trial, daratumumab plus lenalidomide/dexamethasone was associated with superior progression-free survival and response rates versus lenalidomide/dexamethasone alone among patients who were previously treated with bortezomib or who were bortezomib-refractory or lenalidomide-naïve.

Clinical outcomes were better when daratumumab was added to a regimen of patients with relapsed/refractory multiple myeloma who received prior therapy.
Pharmacokinetic analysis of daratumumab as part of combination regimens identified no clinical or demographic characteristics that altered exposure and activity of the monoclonal antibody. The findings support the body-weight–based dosing of 16 mg/kg.
Data from a “real-world” historical cohort of heavily pretreated patients in the Czech Republic confirmed the benefits shown in clinical trials of single-agent daratumumab compared with treatment by physician’s choice.
Page 1 of 8
Results 1 - 10 of 74